Innate Pharma (IPHA) shares rallied 29% on positive phase 2 trial data for monalizumab plus durvalumab in non-small cell lung cancer patients.
Surface Oncology (SURF) shares rose 14% following an uptick in the previous session.
Beigene (BGNE) shares surged 14% after the company received a positive opinion from a key European Medicines Agency committee recommending approval of brukinsa to treat Waldenstrom's macroglobulinemia.